Aisling Capital, a late-stage life sciences investment firm that partners with companies to successfully bring novel medical therapies to market, today announced the closing of its newest fund, with $280 million in...
Give your career or business idea the boost
it needs and sign up to our newsletter today!
Strictly Necessary Cookies
Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.
If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.